{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:40:38Z","timestamp":1784616038903,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pharma.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T15:58:04Z","timestamp":1772294284000},"page":"703-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Organisation du circuit pharmaceutique des MTI en France\u00a0: vers une lecture capacitaire. Une enqu\u00eate de pratiques de la Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO)"],"prefix":"10.1016","volume":"84","author":[{"given":"Isabelle","family":"Madelaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-3518","authenticated-orcid":false,"given":"Bertrand","family":"Pourroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.02.009_bib0135","unstructured":"Directive 2004\/27\/EC of the European Parliament and of the Council of 31\u00a0March 2004\u00a0amending Directive 2001\/83\/EC on the Community code relating to medicinal products for human use."},{"key":"10.1016\/j.pharma.2026.02.009_bib0140","unstructured":"Regulation (EC) No. 1394\/2007\u00a0of the European Parliament and of the Council of 13\u00a0November 2007\u00a0on advanced therapy medicinal products."},{"key":"10.1016\/j.pharma.2026.02.009_bib0145","unstructured":"Soci\u00e9t\u00e9 Fran\u00e7aise de Th\u00e9rapie Cellulaire et G\u00e9nique. D\u00e9finition de la th\u00e9rapie g\u00e9nique [Internet]. Disponible sur\u00a0: https:\/\/www.sftcg.fr\/patients-et-grand-public\/dictionnaire-de-la-therapie-genique.aspx."},{"key":"10.1016\/j.pharma.2026.02.009_bib0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jcyt.2025.04.065","article-title":"The pharmaceutical circuit of advanced therapy medicinal products\u00a0\u2013\u00a0guidelines of the French Society for Oncology Pharmacy","volume":"27","author":"Pourroy","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.pharma.2026.02.009_bib0155","unstructured":"ANSM. Bonnes pratiques de pr\u00e9paration. 2023."},{"key":"10.1016\/j.pharma.2026.02.009_bib0160","unstructured":"D\u00e9cret no\u00a02019-489\u00a0du 21\u00a0mai 2019\u00a0relatif aux pharmacies \u00e0 usage int\u00e9rieur."},{"key":"10.1016\/j.pharma.2026.02.009_bib0165","doi-asserted-by":"crossref","first-page":"1324602","DOI":"10.3389\/fmed.2024.1324602","article-title":"Forecasting the potential impact of cell and gene therapies in France","volume":"11","author":"Lee","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.pharma.2026.02.009_bib0170","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1136\/ejhpharm-2023-004062","article-title":"European Association of Hospital Pharmacists (EAHP) guidance on the pharmacy handling of in vivo gene therapy medicinal products","volume":"31","author":"Genestar","year":"2024","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.pharma.2026.02.009_bib0175","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique. Recommandations sur le circuit hospitalier des m\u00e9dicaments de th\u00e9rapie innovante. 2015. Disponible sur\u00a0: https:\/\/www.sfpo.com."},{"key":"10.1016\/j.pharma.2026.02.009_bib0180","unstructured":"Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique. Livre blanc SFPO\u00a0\u2013\u00a0M\u00e9dicaments de th\u00e9rapie innovante. Septembre 2024. Disponible sur\u00a0: https:\/\/www.sfpo.com."},{"issue":"6","key":"10.1016\/j.pharma.2026.02.009_bib0185","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.pharma.2025.07.005","article-title":"Oncology pharmacy practice: key insights, challenges, and perspectives\u00a0\u2013\u00a0a position paper from the French Society for Oncology Pharmacy (SFPO)","volume":"83","author":"Ranchon","year":"2025","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2026.02.009_bib0190","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.pharma.2023.04.001","article-title":"Circuit pharmaceutique du m\u00e9dicament de th\u00e9rapie innovante (MTI) en France\u00a0: \u00e9tat des lieux et perspectives","volume":"81","author":"Fabri","year":"2023","journal-title":"Ann Pharm Fr"},{"issue":"2","key":"10.1016\/j.pharma.2026.02.009_bib0200","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1136\/ejhpharm-2024-004454","article-title":"Involvement of the hospital pharmacist in securing the chimeric antigen receptor (CAR)-T cell circuit","volume":"33","author":"Bryla","year":"2026","journal-title":"Eur J Hosp Pharm"},{"issue":"14","key":"10.1016\/j.pharma.2026.02.009_bib0205","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/ajhp\/zxad071","article-title":"A call to action: health-system pharmacists must stand up to meet the growing demand for cellular-based therapies","volume":"80","author":"Blind","year":"2023","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.pharma.2026.02.009_bib0210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/14712598.2018.1495192","article-title":"hospital pharmacy departments ready for the rise of gene therapy medicinal products?","volume":"18","author":"Stoner","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pharma.2026.02.009_bib0215","series-title":"Protocole d\u2019utilisation th\u00e9rapeutique et de recueil d\u2019informations\u00a0\u2013\u00a0Obnitix\u00ae","year":"2023"},{"issue":"10427","key":"10.1016\/j.pharma.2026.02.009_bib0220","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2026.02.009_bib0225","series-title":"VYJUVEK: summary of product characteristics [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2026.02.009_bib0230","series-title":"CARVYKTI: summary of product characteristics [Internet]","year":"2024"},{"issue":"1","key":"10.1016\/j.pharma.2026.02.009_bib0235","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12913-024-12026-4","article-title":"The role of hospital pharmacists in supporting the appropriate and safe use of CGT\/ATMPs: a scoping review of current insights","volume":"25","author":"Shi","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.pharma.2026.02.009_bib0240","series-title":"YESCARTA: summary of product characteristics [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2026.02.009_bib0245","series-title":"KYMRIAH: summary of product characteristics [Internet]","year":"2024"},{"key":"10.1016\/j.pharma.2026.02.009_bib0250","doi-asserted-by":"crossref","first-page":"713047","DOI":"10.3389\/fmed.2021.713047","article-title":"ATMP environmental exposure assessment in European Healthcare settings: a systematic review of the literature","volume":"8","author":"Damerval","year":"2021","journal-title":"Front Med"},{"issue":"12","key":"10.1016\/j.pharma.2026.02.009_bib0255","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/oemed-2024-109574","article-title":"Method for the detection and quantification of viral contamination during the preparation of gene therapy drugs in a hospital pharmacy","volume":"81","author":"Deramoudt","year":"2025","journal-title":"Occup Environ Med"},{"issue":"3","key":"10.1016\/j.pharma.2026.02.009_bib0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.pharma.2024.12.003","article-title":"Handling and decontamination of live medications: what challenges for hospital pharmacies in France?","volume":"83","author":"Riazi","year":"2025","journal-title":"Ann Pharm Fr"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:21:40Z","timestamp":1781220100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003450926000349"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.02.009","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Organisation du circuit pharmaceutique des MTI en France\u00a0: vers une lecture capacitaire. Une enqu\u00eate de pratiques de la Soci\u00e9t\u00e9 fran\u00e7aise de pharmacie oncologique (SFPO)","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}